Results 191 to 200 of about 10,388,998 (324)

Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pediatric drug development has achieved remarkable success in the last 20 years with over 1,000 products studied in pediatric patients. This success has been driven in part by an increased understanding of pediatric disease processes. The aspect that has been largely overlooked is the potential adverse effect of new drugs on pediatric developmental ...
Gilbert J. Burckart   +6 more
wiley   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland   +48 more
wiley   +1 more source

What Drives CSR Performance: Structures, Declarations or Values?

open access: yesCorporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT Sustainability and corporate social responsibility (CSR) are increasingly central to strategic management, yet a gap persists between formal commitments and actual practice. The study explores the structural and value‐based predictors of the institutional integration of CSR and sustainability, with a focus on the mediating role of the CSR ...
Pavla Vrabcová   +3 more
wiley   +1 more source

A Pilot Randomized Controlled Trial of Eye Movement Desensitization and Reprocessing Therapy for Adults With Binge‐Eating Disorder

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Binge‐eating disorder (BED) is a serious psychological condition, often associated with trauma, as well as many critical physical and psychological consequences. Despite the availability of several evidence‐based treatments, full remission rates and long‐term recovery rates remain suboptimal.
Amaani H. Hatoum   +5 more
wiley   +1 more source

Nanofiber PVA‐Based Membranes Incorporating Functionalized Spanish Broom Derivatives for Sustainable Water Purification

open access: yesENERGY &ENVIRONMENTAL MATERIALS, EarlyView.
This study investigates Spanish broom (Spartium junceum) as a renewable source for electrospun composite membranes in sustainable water purification. MCC and biochar were functionalized with eco‐friendly precursors and nanomaterials (i.e., HNT, β‐CDs) to develop hybrid PVA nanofiber composites.
Giulia Rando   +7 more
wiley   +1 more source

Preclinical signal for a disease‐modifying effect on seizure cluster severity with intermittent diazepam treatment

open access: yesEpilepsia, EarlyView.
Abstract Objective In epilepsy, daily treatment provides only symptomatic seizure control, leaving a significant unmet need for a treatment that affects the underlying predisposition to seizures. Here, in a first‐of‐its‐kind study, we test the hypothesis that intermittent treatment of seizure clusters with diazepam in the kainic acid post‐status ...
Qian Wu   +8 more
wiley   +1 more source

Quantifying the impact of a computer‐aided diagnostic score on the clinical diagnosis of functional seizures

open access: yesEpilepsia, EarlyView.
Abstract Objective The diagnosis of functional/dissociative seizures (FDS) without ictal video‐electroencephalography is challenging. The Functional/Dissociative Seizures Likelihood Score (FSLS) is a machine learning‐based diagnostic score that aims to help clinicians identify FDS.
Wesley T. Kerr   +38 more
wiley   +1 more source

L‐Relationship between uncertainty and average seizure frequency in clinical trials of antiseizure medications

open access: yesEpilepsia, EarlyView.
Abstract Objective Antiseizure medications are approved based on clinical trials that demonstrate their efficacy as measured by reductions in seizure frequency (SF). When designing these trials, trialists must select inclusion criteria where SF can be reliably measured to maintain statistical power.
Wesley T. Kerr   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy